Search Results
Sep 09, 2026, 09:00 ET First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA
In this context, extending the duration of action and improving dosing convenience have become important areas of innovation in metabolic disease R&D. The treatment landscape is rapidly evolving - from long‑acting injectables to once-weekly oral formulations - reflecting the demand for patient‑centric
More news about: Gan & Lee Pharmaceuticals
Sep 09, 2026, 09:00 ET Silicon Motion Earns ISO/SAE 21434 Automotive Cybersecurity Process Certification
and electronic systems. The standard also provides a recognized engineering framework that supports compliance with UNECE UN Regulation No. 155 (UN R155), including its Cyber Security Management System (CSMS) requirements for vehicle type approval in the European Union. By establishing common processes,
More news about: Silicon Motion Technology Corporation
Sep 09, 2026, 09:00 ET Hyperquake Brings the Library of Congress Collections to Life for Young Researchers Through Digital Interactive Design at The Source
development for The Source was initially led by Potion, the acclaimed digital storytelling studio Hyperquake acquired in 2024. Guided by Founder Philip R. Tiongson and produced by longtime Potion team members including Claire Bradley, the project reflects the studio's legacy of inclusive, research-driven
More news about: Hyperquake
Sep 09, 2026, 09:00 ET Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate U.S. Growth and Oncology Innovation
Executive Chairman of the Board of Rakuten Medical. "Christophe's extensive experience in global business leadership and Ken's deep expertise in oncology R&D will be invaluable as we continue to build the company for long-term success. Together with our strengthened leadership team, we will further enhance
More news about: Rakuten Medical, Inc.
Sep 09, 2026, 08:59 ET Euno Raises $23 Million Series A to Build the AI Context Brain for the Enterprise
IDF cybersecurity department. Firstenberg, who leads the company's San Francisco office, was a section head in Unit 8200 and then served as VP of R&D at LightCyber, which was acquired by Palo Alto Networks. The company employs nearly 30 people across the US and Israel, including a context-focused
More news about: Euno
Sep 09, 2026, 08:55 ET MCatalysis Closes $5M Seed Round to Produce Low-Carbon Fuel below Commodity Cost
de la Chimie. Locating in this industrial corridor enables the company to leverage established infrastructure and chemical engineering talent. R&D efforts will continue to be centered in London."Cost is everything; businesses cannot switch energy sources if alternatives carry a premium,"
More news about: MCatalysis, Inc.
Sep 09, 2026, 08:31 ET Experience Living Agricultural History at the "Granville Gold: Mock Tobacco Auction" on September 27 in Oxford, North Carolina
& Tobacco Author (919) 7714, [email protected] Frank Timberlake, R F Timberlake & Company (919) 269-4300 OF or (919) 805-0055 CELL, [email protected]
More news about: The Granville County Historical Society & Museum
Sep 09, 2026, 08:14 ET Saab receives order from FMV for further work on future concept
https://news.cision.com/saab/r/saab-receives-order-from-fmv-for-further-work-on-future-concept,c4393881The following files are available for download:
More news about: Saab
Sep 09, 2026, 08:00 ET Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
/PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its subsidiary, HJB, have entered into a technology licensing and
More news about: Transcenta Therapeutics
Sep 09, 2026, 08:00 ET MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
DA-1726DA-1726 is a novel GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading
More news about: MetaVia Inc.
Sep 09, 2026, 08:00 ET LG ULTRAGEAR BECOMES OFFICIAL GAMING MONITOR PARTNER OF SIM GAMING EXPO 2026
expo's gaming arena will feature 15 LG 34-inch OLED UltraGear 21:9 gaming monitors with a 240Hz refresh rate, WQHD resolution, 0.03ms response time and 800R curvature, delivering an immersive, high-performance experience for competitive sim racing.LG will also provide 32-inch 4K UHD monitors for broadcast
More news about: LG Electronics USA
Sep 09, 2026, 08:00 ET Daesang Targets Global Pharmaceutical Amino Acid Market, Building on 70 Years of Fermentation Technology
nutrition, and the manufacture of cell culture media and excipients for biopharmaceuticals. The company operates an R&D center and a 6,000 m2 production facility in Frellstedt, northern Germany, and maintains established business relationships with global
More news about: Daesang Corporation
Sep 09, 2026, 08:00 ET Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose heterobifunctional radiopharmaceuticals for therapy and imaging that possess
More news about: Ratio Therapeutics Inc.
Sep 09, 2026, 08:00 ET UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy. Last accessed: September 2026.Murvai VR, Galiș R, Panaitescu A, et al. Antiphospholipid syndrome in pregnancy: a comprehensive literature review. BMC Pregnancy Childbirth. 2025;25:230.Alijotas-Reig
More news about: UCB
Sep 09, 2026, 07:56 ET Kapital Raises $125M in New Financing from Tru Arrow Partners, Fasanara Capital
/C O R R E C T I O N -- Kapital/ In the news release, Kapital Raises $125M in New Financing from Tru Arrow Partners, Fasanara Capital, issued Sept. 9, 2026 by Kapital over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with
More news about: Kapital
Sep 09, 2026, 07:22 ET Archway Endodontics Celebrates Five Years of Specialty Root Canal Care in St. Louis
Archway Endodontics marks its five-year milestone in September 2026, with Dr. Brian R. Judd, DDS, MS, having treated patients at the St. Louis endodontic practice since the day it opened.ST. LOUIS, Sept. 9, 2026
More news about: Archway Endodontics
Sep 09, 2026, 07:12 ET Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.Our proprietary antibody technology
More news about: Harbour BioMed
Sep 09, 2026, 07:03 ET /C O R R E C T I O N -- Panasonic Connect Europe/
More news about: Panasonic Connect Europe
Sep 09, 2026, 07:00 ET Eltek Ltd. Announces CEO Transition: Retirement of Eli Yaffe and Appointment of Ron Freund as the Company's CEO
defense, aerospace and medical industries in Israel, the United States, Europe and Asia.Eltek was founded in 1970. The Company's headquarters, R&D, production and marketing center are located in Israel. Eltek also operates through its subsidiary in North America and by agents and distributors
More news about: Eltek Ltd.
Sep 09, 2026, 06:55 ET Yutong wprowadza na rynek europejski autokar premium T14
dalekobieżnymi i rozszerzając ofertę serii T.ZHENGZHOU, Chiny, 9 września 2026 r. /PRNewswire/ -- Yutong wprowadził na rynek T14, autokar turystyczny klasy premium zaprojektowany z myślą o rynku europejskim. Nowy model z silnikiem
More news about: Yutong
Sep 09, 2026, 06:17 ET Aurzen glänzt auf der IFA 2026 und erhält elf Auszeichnungen für sein Projektor-Sortiment
hervorgehoben wurde.Der Aurzen ZIP Pro und der EAZZE E1R wurden beide mit einem Netzwelt Innovation Award ausgezeichnet und gehörten zu den 58 innovativsten Produkten auf der IFA 2026. Das Web-Portal hob das kompakte Design des E1R und den integrierten Roku-Fernseher als Alternative
More news about: Aurzen
Sep 09, 2026, 06:00 ET RBC to mobilize $1.4 billion to back Canada's next global technology champions and advance nation-building efforts
greater potential for innovation and economic growth.Strong R&D culture – Canada ranks 2nd in the G7 for direct government funding and tax support for business R&D.Competitive tax policies – At 13 per cent, Canada's tax
More news about: RBC Royal Bank
Sep 09, 2026, 06:00 ET RBC to mobilize $1.4 billion to back Canada's next global technology champions and advance nation-building efforts
greater potential for innovation and economic growth.Strong R&D culture – Canada ranks 2nd in the G7 for direct government funding and tax support for business R&D.Competitive tax policies – At 13 per cent, Canada's tax
More news about: RBC Royal Bank
Sep 09, 2026, 06:00 ET King's Hawaiian Teams Up with Taylor Hanson to Drop "MMMBites" in Celebration of New Soft Swirl Cinnamon Bites
[email protected] King's Hawaiian®Founded 75 years ago in Hilo, Hawaii, by Robert R. Taira, KING'S HAWAIIAN is a family-owned business that has been dedicated to providing Hawaii-inspired foods made with original recipes and Aloha Spirit
More news about: King's Hawaiian
Sep 09, 2026, 06:00 ET IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than
More news about: IDEAYA Biosciences, Inc.